乌帕替尼治疗类风湿关节炎的安全性分析:SELECT III期临床项目整合分析
该整合分析基于五项随机对照III期试验,评估乌帕替尼15 mg和30 mg每日一次治疗中重度活动性类风湿关节炎(RA)的安全性。共3834例患者接受乌帕替尼治疗,总暴露4020.1患者年。结果显示,与阿达木单抗相比,乌帕替尼组带状疱疹和肌酸磷酸激酶(CPK)升高发生率更高;严重感染率与阿达木单抗相似但高于甲氨蝶呤;死亡、恶性肿瘤、主要不良心血管事件(MACE)和静脉血栓栓塞事件(VTE)率在各治疗组间相似。
要点
- 乌帕替尼15 mg和30 mg组带状疱疹及CPK升高发生率高于甲氨蝶呤和阿达木单抗。
- 严重感染率与阿达木单抗相似,但高于甲氨蝶呤。
- 死亡、恶性肿瘤、MACE和VTE发生率在各治疗组间相似。
核心结论
- 乌帕替尼治疗RA患者中带状疱疹和CPK升高风险高于阿达木单抗,但恶性肿瘤、MACE和VTE发生率与甲氨蝶呤或阿达木单抗相似。
研究设计与样本
- 整合分析五项随机、安慰剂或阳性对照的III期试验,评估乌帕替尼15 mg和30 mg每日一次治疗RA的安全性。
- 共3834例患者接受乌帕替尼15 mg(n=2630)或30 mg(n=1204),总暴露4020.1患者年。
主要发现
- 乌帕替尼组最常见治疗中出现的不良事件(TEAE)为上呼吸道感染、鼻咽炎和尿路感染。
- 严重感染率在乌帕替尼15 mg与阿达木单抗之间相似,但高于甲氨蝶呤。
- 带状疱疹和CPK升高发生率在乌帕替尼两个剂量组均高于甲氨蝶呤和阿达木单抗,胃肠穿孔率在乌帕替尼30 mg组更高。
- 死亡、恶性肿瘤、经裁定的MACE和VTE发生率在各治疗组间相似。
关键数值与推荐
- 暴露调整事件率按安慰剂(3项试验;12/14周)、甲氨蝶呤(2项试验;平均暴露36周)、阿达木单抗(1项试验;平均暴露42周)、乌帕替尼15 mg(5项试验;平均暴露53周)和乌帕替尼30 mg(4项试验;平均暴露59周)汇总。
临床怎么用
- 使用乌帕替尼治疗RA时应关注带状疱疹和CPK升高的风险,尤其与阿达木单抗相比。
- 乌帕替尼30 mg组胃肠穿孔率更高,需警惕。
- 严重感染风险与阿达木单抗相似但高于甲氨蝶呤,治疗前应评估感染风险。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This integrated analysis presents the safety profile of upadacitinib, a Janus kinase inhibitor, at 15 mg and 30 mg once daily in patients with moderately to severely active rheumatoid arthritis (RA). METHODS: Treatment-emergent adverse events (TEAEs) and laboratory data from five randomised, placebo- or active-controlled phase III trials of upadacitinib for patients with RA were analysed and summarised. Exposure-adjusted event rates are shown for placebo (three trials; 12/14 weeks), methotrexate (two trials; mean exposure: 36 weeks), adalimumab (one trial; mean exposure: 42 weeks), upadacitinib 15 mg (five trials; mean exposure: 53 weeks) and upadacitinib 30 mg (four trials; mean exposure: 59 weeks). RESULTS: 3834 patients received one or more doses of upadacitinib 15 mg (n=2630) or 30 mg (n=1204), for a total of 4020.1 patient-years of exposure. Upper respiratory tract infection, nasopharyngitis and urinary tract infection were the most commonly reported TEAEs with upadacitinib. Rates of serious infection were similar between upadacitinib 15 mg and adalimumab but higher compared with methotrexate. Rates of herpes zoster and creatine phosphokinase (CPK) elevations were higher in both upadacitinib groups versus methotrexate and adalimumab, and rates of gastrointestinal perforations were higher with upadacitinib 30 mg. Rates of deaths, malignancies, adjudicated major adverse cardiovascular events (MACEs) and venous thromboembolic events (VTEs) were similar across treatment groups. CONCLUSION: In the phase III clinical programme for RA, patients receiving upadacitinib had an increased risk of herpes zoster and CPK elevation versus adalimumab. Rates of malignancies, MACEs and VTEs were similar among patients receiving upadacitinib, methotrexate or adalimumab. TRIAL REGISTRATION NUMBERS: SELECT-EARLY: NCT02706873; SELECT-NEXT: NCT02675426; SELECT-COMPARE: NCT02629159; SELECT-MONOTHERAPY: NCT02706951; SELECT-BEYOND: NCT02706847.
引用
- Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020. PMID: 33115760. doi:10.1136/annrheumdis-2020-218510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。